English 
デジタルヘルス分野で革新的な医療機器を開発するクオドリティクス株式会社は、シリーズAラウンドにおいて、ライフタイムベンチャーズ、京都キャピタルパートナーズ、クロステックベンチャーズ、個人投資家を引受先とする第三者割当増資を実施し、総額3億円の資金調達を行いました。
In addition, on September 11, 2024, the company was selected for the New Energy and Industrial Technology Development Organization (NEDO)’s Deep Tech Startup Support Project (STS Phase), which will provide a subsidy of up to 300 million yen. This brings the total amount raised in this series to 600 million yen.
We are developing a programmable medical device called the “epileptic seizure warning device” (tentative name, generic name: epilepsy alarm) that uses a wearable device to detect signs of epileptic seizures in real time and warn patients a few minutes before a seizure occurs.
こちらもお読みください： SCSK、健康管理サービス「Uwell」を開始
今回集まった資金は、以下の目的に使用されます：
日本における臨床試験の実施
オーストラリアと米国における薬事承認と償還戦略の推進
グローバル市場における事業展開と品質管理体制
Professor Patrick Kwan of Monash University’s Department of Neuroscience, an international leader in epilepsy research and a clinical researcher focusing on personalized medicine and the application of AI, said, “Epilepsy seizures are difficult to predict and have a significant impact on patients’ quality of life. The technology Quadritics is developing offers the potential to provide early warning of the signs of a seizure, helping patients live safer and more secure lives. From the perspective of personalized medicine, I hope that this type of non-invasive approach will be applied clinically and that it will benefit even more patients.”
The company is adopting a strategy to aim for US FDA approval, using pharmaceutical approval in Australia and insurance reimbursement through the NDIS (Disability Insurance Scheme) as a foothold. In 2024, the company was selected as the first Japanese company for MedTech Actuator’s acceleration program “Cohort 9”, and established an Australian subsidiary, “Quadlytics Pty Ltd”. It is currently building a business strategy for expansion into Australia and the US, with the goal of launching the product in Australia in 2028.
Buzz Palmer, CEO of MedTech Actuator, a physician, serial entrepreneur, and someone who has supported numerous medical startups, said, “Japan is home to a wealth of innovative early-stage technologies and ideas. It’s inspiring to meet teams like クアドリティックス that are turning these into products and businesses that can be deployed globally. We look forward to seeing startups like them further strengthen the health tech ecosystem connecting Australia, Japan, and the Asia-Pacific region.”
また、MedTech Actuator社も今回のラウンドで当社の株主となり、協力関係をさらに深め、さらなる支援を受けることを期待しています。
In the United States, the company has been selected for the innovation support programs “Mayo Clinic Platform Accelerate” and “Mayo Clinic Innovation Exchange” run by Mayo Clinic, and in collaboration with some of the world’s largest medical institutions, is advancing clinical research and regulatory strategies for expansion into the U.S. market. Currently, the company is proceeding with phased demonstration and regulatory preparations with the aim of expanding into the U.S. in 2030.
ソース PRタイムズ
日本語